Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the US Market
10 December 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. has launched Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan (valsartan) Tablets approved by the US Food and Drug Administration (USFDA), the company said.

The Diovan brand and generic market had US sales of approximately USD 150m MAT for the most recent twelve months ending in October 2021 according to IQVIA Health.

Dr. Reddy's Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.

Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) is an integrated pharmaceutical company.

Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.

Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.


Related Headlines